<DOC>
	<DOCNO>NCT01652573</DOCNO>
	<brief_summary>X-linked hypophosphatemia ( XLH ) common form inherited rickets United States . It also cause bone disease adult . XLH cause overproduction hormone call FGF23 , make body waste phosphate . This study design determine nasal calcitonin , already approve drug US , low blood level FGF23 reduce phosphate wasting patient XLH . In study investigator : 1 . Determine whether nasal calcitonin significantly lower integrate 24-hour blood level FGF23 patient XLH . 2 . Evaluate whether nasal calcitonin improve serum phosphate level XLH . 3 . Assess whether nasal calcitonin improve blood level active form vitamin D calcium absorption intestine . 4 . Make sure nasal calcitonin safe well tolerate .</brief_summary>
	<brief_title>Calcitonin Treating X-linked Hypophosphatemia</brief_title>
	<detailed_description>The pathophysiology X-linked hypophosphatemia ( XLH ) clarify report 1995 HYP Consortium lead Dr. Michael Econs , mutation neutral endopeptidase PHEX , genetic basis disorder ( Nature Genetics 11:130 ) . By pathway remains unclear , loss-of-function mutation PHEX lead elevate circulating level FGF23 . It well establish FGF23 proximate biological mediator syndrome . FGF23 suppress renal tubular phosphate reabsorption inhibit transcription major sodium phosphate co-transporters proximal renal tubule . In addition , suppress 1-α hydroxylase activity lead low low-normal serum level 1,25 ( OH ) 2vitamin D. This turn impair intestinal phosphate calcium absorption . These combined biochemical abnormality lead persistent defect skeletal mineralization manifest rickets child osteomalacia adult . Conventional therapy XLH consist oral therapy phosphate supplement calcitriol require ingestion medication 4-6 time daily . There several limitation conventional therapy include inability correct growth retardation child enthesopathy frequently see adult . Furthermore , clear therapeutic approach cause rise circulate level FGF23 XLH . Thus , urgent need appropriate therapy direct basic pathophysiology disorder . As detailed Research Strategy , identify calcitonin novel suppressor FGF23 production XLH . A single , subcutaneous injection calcitonin result sustain fall FGF23 level persist 16 hour drug administration ; change observe control subject . The fall serum FGF23 associate rise serum phosphate circulating level 1,25 ( OH ) 2vitamin D. These data excite suggest novel therapy XLH . This exploratory clinical trial seek establish efficacy calcitonin improve biochemical abnormality untreated adult XLH . We test hypothesis calcitonin , lower circulating level FGF23 raise serum level 1,25 ( OH ) 2vitamin D , improve phosphate homeostasis patient XLH . To test hypothesis pursue follow specific aim : 1 . Determine whether 3 month nasal calcitonin administer dose 400 IU/day significantly lower integrated 24-hour serum level FGF23 patient XLH . 2 . Evaluate whether nasal calcitonin improve phosphate homeostasis raise TmP/GFR integrate 24 hr . serum phosphate concentration . 3 . Assess whether nasal calcitonin improve calcium metabolism patient XLH increase integrate 24 hr . serum level 1,25 ( OH ) 2vitamin D enhance intestinal calcium absorption , estimate 24-hour urine calcium . 4 . Confirm nasal calcitonin well tolerate quantify side effect nasal irritation trial . If successful , study provide proof-of-principal novel use FDA-approved drug treat XLH . This approach , unlike conventional treatment , address underlie pathophysiology disorder would represent first therapeutic advance XLH 30 year .</detailed_description>
	<mesh_term>Rickets</mesh_term>
	<mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
	<mesh_term>Hypophosphatemia</mesh_term>
	<mesh_term>Rickets , Hypophosphatemic</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>age ≥18 great establish diagnosis XLH fast serum calcium ≤10.5 mg/dl fast PTH time screen &lt; /= 1.7 time upper limit normal estimate creatinine clearance &lt; 60 cc/min and/or serum creatinine &gt; 1.5 mg/dl ; serum 25 ( OH ) vitamin D &lt; 30 ng/ml . Potential study subject serum 25 ( OH ) vitamin D &lt; 30 ng/ml supplement 25 ( OH ) vitamin D achieve serum value &gt; 30 ng/ml screen inability comply instruction appropriate follow visit treatment agent may skeletal metabolism glucocorticoid , bisphosphonates , denosumab , teriparatide , estrogen anticonvulsant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>X link hypophosphatemia</keyword>
	<keyword>calcitonin</keyword>
	<keyword>FGF twenty three</keyword>
</DOC>